tiprankstipranks
Trending News
More News >
kneat.com (TSE:KSI)
TSX:KSI

kneat.com (KSI) AI Stock Analysis

Compare
103 Followers

Top Page

TSE:KSI

kneat.com

(TSX:KSI)

Select Model
Select Model
Select Model
Neutral 55 (OpenAI - 5.2)
Rating:55Neutral
Price Target:
C$5.00
▼(-2.53% Downside)
Kneat.com's overall stock score reflects strong SaaS revenue growth and high customer satisfaction, which are offset by profitability challenges and cash flow constraints. The technical indicators suggest a bearish trend, and the valuation is unattractive due to a negative P/E ratio. Strategic investments in R&D are promising, but increased operating expenses and macroeconomic headwinds pose risks.
Positive Factors
SaaS Revenue Growth
Strong SaaS revenue growth indicates robust demand for Kneat's software solutions, enhancing long-term revenue stability and market position.
High Customer Satisfaction
High customer satisfaction reflects strong product quality and service, likely leading to customer retention and competitive advantage.
Strategic R&D Investments
Strategic R&D investments ensure Kneat remains at the forefront of innovation, supporting long-term growth and market leadership.
Negative Factors
Increased Operating Expenses
Rising operating expenses can pressure profit margins and delay profitability, affecting financial health if not managed effectively.
Macroeconomic Headwinds
Macroeconomic headwinds could slow growth and expansion, impacting Kneat's ability to capitalize on market opportunities.
Competitive Pressures
Rising competition may affect Kneat's market share and pricing power, potentially slowing revenue growth and deal closures.

kneat.com (KSI) vs. iShares MSCI Canada ETF (EWC)

kneat.com Business Overview & Revenue Model

Company Descriptionkneat.com, inc. designs, develops, and supplies software for data and document management within regulated environments in the United States, Ireland, Canada, and internationally. The company offers Kneat Gx platform, a configurable commercial off-the-shelf application focused on validation lifecycle management and testing for biotechnology, pharmaceutical, and medical device manufacturing industries. Its platform is used in process, computer system, cleaning, analytical instrument, method, utility and facility, equipment, and cold chain validation, as well commissioning and qualification, and electronic logbook management. The company also provides software-related services, including training, installation, upgradation, consulting, and maintenance, as well as process mapping, project management, and other services. kneat.com, inc. is headquartered in Limerick, Ireland.
How the Company Makes MoneyKneat.com generates revenue primarily through a subscription-based model, where clients pay for access to its software solutions on a recurring basis. This includes annual licensing fees for the Kneat GxP platform, which vary based on the scale of implementation and the number of users. Additionally, the company earns revenue from professional services, which can include implementation support, training, and consulting services to help clients optimize their use of the software. Key partnerships with industry leaders and regulatory bodies also enhance Kneat's credibility and market reach, contributing to its earnings by attracting a larger client base seeking reliable compliance solutions.

kneat.com Earnings Call Summary

Earnings Call Date:Nov 12, 2025
(Q3-2025)
|
% Change Since: |
Next Earnings Date:Feb 25, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted strong growth in SaaS revenue and customer satisfaction, supported by strategic investments in R&D. However, the significant increase in operating expenses and the impact of macroeconomic challenges and competitive pressures were noted as concerns.
Q3-2025 Updates
Positive Updates
Strong SaaS Revenue Growth
SaaS revenue grew 33% year-over-year, outperforming the average for companies of similar size.
High Customer Satisfaction
Kneat received a satisfaction score of 98 out of 100 in the G2 report, significantly higher than the second-ranked score of 78.
Annual Recurring Revenue Increase
Annual recurring revenue increased by 37% to $68.6 million compared to the previous year.
Overall Revenue Growth
Total revenue for Q3 2025 increased by 26% to $16.1 million compared to Q3 2024.
Strategic R&D Investments
Continued investment in R&D and AI strategy to enhance product capabilities and maintain market leadership.
Negative Updates
Increased Operating Expenses
Operating expenses grew 43% year-over-year in Q3 2025, impacting profitability.
Decline in Services Revenue
Services revenue decreased to $0.9 million from $1.2 million in Q3 2024, indicating a shift of service responsibilities to partners.
Macroeconomic Headwinds
Challenges related to tariffs, trade uncertainty, and customer budget constraints affecting expansion plans.
Competitive Pressures
Increased competition from entrants like Veeva, which could potentially slow down deal closures.
Company Guidance
During the Kneat Third Quarter 2025 Earnings Call, the company reported a strong performance with SaaS revenue growing by 33% year-over-year, significantly surpassing the average growth for similar-sized companies. Total revenue for the quarter increased by 26% to $16.1 million, while gross profit rose by 25% to $12.2 million. The company ended the quarter with an annual recurring revenue (ARR) of $68.6 million, up 37% from the previous year. Operating expenses saw a 43% rise, driven by a 47% increase in R&D and a 45% increase in sales and marketing expenses. Despite macroeconomic headwinds affecting buying cycles, Kneat maintained a robust sales pipeline and continued to invest strategically in R&D and go-to-market strategies. The company's competitive edge was highlighted by a satisfaction score of 98 out of 100 from G2's software review, well ahead of competitors. Kneat aims to achieve profitability and cash flow breakeven in 2026, targeting adjusted EBITDA margins typical of SaaS companies in the late 20s to early 30s percentage range.

kneat.com Financial Statement Overview

Summary
kneat.com demonstrates strong revenue growth and a solid gross profit margin, indicating effective cost management. However, profitability remains a concern with negative net profit margins. The balance sheet shows improved leverage and a strong equity base, but returns on equity are low. Cash flow generation is improving, but free cash flow remains negative. Overall, the company is on a positive trajectory but needs to enhance profitability and cash flow generation to strengthen its financial position.
Income Statement
The company has shown a strong revenue growth rate of 7.05% in the TTM period, indicating positive momentum. Gross profit margin remains robust at 75.11%, reflecting efficient cost management. However, the net profit margin is negative at -4.24%, highlighting profitability challenges. The EBIT margin is slightly positive at 3.10%, but the company needs to improve its operational efficiency to enhance profitability.
Balance Sheet
The debt-to-equity ratio has improved to 0.37 in the TTM period, indicating a more balanced capital structure. Return on equity is low at 0.83%, suggesting limited returns for shareholders. The equity ratio stands at 49.29%, showing a solid equity base. Overall, the balance sheet reflects moderate financial stability with room for improvement in profitability.
Cash Flow
Operating cash flow has improved significantly, with a positive operating cash flow to net income ratio of 0.41. However, free cash flow remains negative, although it has shown substantial growth. The free cash flow to net income ratio is negative, indicating challenges in generating free cash flow relative to net income. The company needs to focus on improving cash flow generation to support growth.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue60.00M48.94M34.22M23.75M15.50M7.42M
Gross Profit41.84M36.76M23.13M14.65M9.32M2.88M
EBITDA15.43M6.27M-5.37M-3.20M-5.11M-2.30M
Net Income-1.19M-7.73M-14.12M-9.15M-9.86M-5.88M
Balance Sheet
Total Assets131.74M124.58M64.50M50.41M51.28M33.80M
Cash, Cash Equivalents and Short-Term Investments59.84M58.89M15.25M12.28M21.56M8.66M
Total Debt30.00M29.26M28.17M7.09M7.86M9.52M
Total Liabilities65.51M59.51M49.73M24.43M17.09M14.59M
Stockholders Equity66.23M65.07M14.76M25.98M34.19M19.21M
Cash Flow
Free Cash Flow-1.56M-10.09M-18.39M-9.82M-7.74M-9.28M
Operating Cash Flow14.21M9.79M-1.28M2.99M2.31M-1.98M
Investing Cash Flow-19.61M-17.52M-15.97M-11.91M-10.04M-6.43M
Financing Cash Flow28.78M50.62M20.27M-383.91K21.20M13.11M

kneat.com Technical Analysis

Technical Analysis Sentiment
Positive
Last Price5.13
Price Trends
50DMA
4.71
Positive
100DMA
5.15
Negative
200DMA
5.65
Negative
Market Momentum
MACD
0.11
Negative
RSI
65.71
Neutral
STOCH
81.68
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:KSI, the sentiment is Positive. The current price of 5.13 is above the 20-day moving average (MA) of 4.77, above the 50-day MA of 4.71, and below the 200-day MA of 5.65, indicating a neutral trend. The MACD of 0.11 indicates Negative momentum. The RSI at 65.71 is Neutral, neither overbought nor oversold. The STOCH value of 81.68 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:KSI.

kneat.com Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
68
Neutral
C$555.06M171.401.45%59.34%-23.48%
55
Neutral
C$489.07M-380.00-2.45%33.27%86.18%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
50
Neutral
C$35.65M-7.34-48.53%-9.66%
48
Neutral
C$64.58M-4.36-207.53%7.04%
44
Neutral
C$13.82M-2.7748.94%
42
Neutral
C$8.01M-1.7381.01%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:KSI
kneat.com
5.13
-1.04
-16.86%
TSE:ADK
Diagnos
0.35
<0.01
2.94%
TSE:VHI
Vitalhub
9.05
-2.28
-20.12%
TSE:AIDR
Rocket Doctor AI
0.76
0.14
22.58%
TSE:UDOC
UniDoc Health Corp
0.16
-0.32
-67.01%
TSE:NARA
PanGenomic Health, Inc. Class A
0.57
0.41
256.25%

kneat.com Corporate Events

Business Operations and StrategyRegulatory Filings and Compliance
Kneat Solutions Secures Strategic Deal with Global Specialty Chemicals Leader
Positive
Dec 17, 2025

Kneat Solutions has entered a strategic partnership with a global specialty chemicals leader by signing a three-year Master Services Agreement. This collaboration showcases Kneat’s leadership in the digital validation market and positions the company to expand its platform’s influence across adjacent compliance functions while further enhancing efficiency and regulatory standards for its customers. This milestone contributes to Kneat’s record-breaking year in customer acquisition, bolstering the company’s reputation as a trusted provider of digital transformation solutions in highly regulated industries.

The most recent analyst rating on (TSE:KSI) stock is a Hold with a C$5.00 price target. To see the full list of analyst forecasts on kneat.com stock, see the TSE:KSI Stock Forecast page.

Financial Disclosures
Kneat to Release Q3 2025 Financial Results
Neutral
Oct 23, 2025

Kneat.com announced it will release its third-quarter financial results for 2025 on November 12, following the close of the TSX market. The announcement highlights Kneat’s continued focus on transparency and engagement with stakeholders, as the company plans a webcast conference call for analysts the following day. This release is part of Kneat’s ongoing efforts to maintain its leadership in the digital validation industry, providing stakeholders with insights into its financial performance and strategic direction.

The most recent analyst rating on (TSE:KSI) stock is a Hold with a C$6.00 price target. To see the full list of analyst forecasts on kneat.com stock, see the TSE:KSI Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Dec 19, 2025